Jana Armouti

Jana Armouti, Laura Hutchins, Jacob Duplantis et al.

Hospital readmission within 30 days of discharge is a leading driver of morbidity, mortality, and avoidable healthcare expenditure in congestive heart failure (CHF). Current clinical risk stratification tools rely primarily on non-imaging data and exhibit limited predictive performance. Point-of-care lung ultrasound (LUS) offers a sensitive, noninvasive window into the pulmonary congestion that characterizes CHF decompensation, yet its prognostic utility for readmission prediction remains largely unexplored. We present a pilot feasibility study, the first systematic machine learning study using B-mode LUS acquired during hospitalization to predict 30-day CHF readmission. Quantitative spatiotemporal embeddings are extracted from a pretrained Temporal Shift Module (TSM) ResNet-18 encoder, and interpretable biomarker features are separately evaluated. Through structured ablations over lung view, temporal representation, multi-view fusion, and cross-lung augmentation, we identify the key imaging factors driving readmission risk. Our findings reveal that (1) dependent lower-lung regions (Left-3, Right-3) carry the strongest prognostic signal, consistent with their greater susceptibility to hydrostatic congestion; (2) temporal difference features between sequential examinations substantially outperform single-timepoint representations, highlighting the importance of capturing disease trajectory; and (3) multi-view feature concatenation yields the best overall performance, with our top MLP model achieving an F1 score of 0.80 (95% CI: 0.62-0.96). Biomarker analysis further reveals that pleural-line abnormalities, including breaks and indentations, are as informative as the canonical A-line and B-line markers. These results support POCUS-derived biomarkers as practical, interpretable tools for noninvasive CHF risk stratification.

Jana Armouti, Nikhil Madaan, Rohan Panda et al. · cmu

Predicting whether a treatment leads to meaningful improvement is a central challenge in personalized medicine, particularly when disease progression manifests as subtle visual changes over time. While data-driven deep learning (DL) offers a promising route to automate such predictions, acquiring large-scale longitudinal data for each individual patient remains impractical. To address this limitation, we explore whether inter-patient variability can serve as a proxy for learning intra-patient progression. We propose LEARNER, a contrastive pretraining framework that leverages coarsely labeled inter-patient data to learn fine-grained, patient-specific representations. Using lung ultrasound (LUS) and brain MRI datasets, we demonstrate that contrastive objectives trained on coarse inter-patient differences enable models to capture subtle intra-patient changes associated with treatment response. Across both modalities, our approach improves downstream classification accuracy and F1-score compared to standard MSE pretraining, highlighting the potential of inter-patient contrastive learning for individualized outcome prediction.